Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

Annals of Medicine

Volumn 45, Issue 5-6, 2013, Pages 423-429

  Lindhoff Last, Edelgard ^a   Ansell, Jack ^b   Spiro, Theodore ^c   Samama, Meyer Michel ^d,e  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b LENOX HILL HOSPITAL   (United States)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

^d HÔTEL DIEU   (France)

^e Biomnis Laboratory   (France)

Author keywords

Anticoagulants; Laboratory testing; Rivaroxaban

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; RIVAROXABAN;

CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; STEADY STATE; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG OVERDOSE; FACTOR XA; HUMANS; MORPHOLINES; PROTHROMBIN TIME; THIOPHENES;

EID: 84882374529     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.801274     Document Type: Review

References (39)

1. Garcia DA, Baglin TP, Weitz JI, Samama MM . Parenteral 1. anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: E24S- e43S.
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2012; 141: E44S- e88S.
3. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59- 7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Th er. 2005; 78 : 412-21
4. K ubitza D, B ecka M, R oth A, M ueck W. D ose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008; 24: 2757- 65
5. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al . In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3: 514- 21
6. Depasse F, Busson J, Mnich J, Le Flem L, Gerotziafas GT, Samama MM. Eff ect of BAY 59-7939- A novel, oral, direct Factor Xa inhibitor-on clotbound Factor Xa activity in vitro . J Thromb Haemost. 2005; 3(Suppl 1): Abstract P1104
7. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov. 2011; 10: 61- 75
8. Bates SM, Weitz JI. Coagulation assays. Circulation. 2005; 112: E53-60
9. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines . Chest. 2012; 141 : E531S-e575S.
10. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: E419S- e494S.
11. Heni N, Glogner P. Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis . Naunyn- Schmiedeberg's Arch Pharmacol. 1976; 293: 183- 6
12. S amama M M, M artinoli J L, L e Flem L, G uinet C, P lu-Bureau G, Depasse F, et al . Assessment of laboratory assays to measure rivaroxaban-an oral, direct Factor Xa inhibitor . Thromb Haemost. 2010; 103: 815-25
13. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. R ivaroxaban diff erentially infl uences ex vivo global coagulation assays based on the administration time . Thromb Haemost. 2011; 106: 156- 64
14. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct Factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay . Thromb Haemost. 2010; 104: 1263- 71
15. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Eff ects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays . J Thromb Haemost. 2011; 9 : 133-9
16. Lindhoff-Last E, S amama M M, O rtel T L, W eitz J I, S piro T E. A ssays for measuring rivaroxaban: Their suitability and limitations . Th er Drug Monit. 2010; 32 : 673-9
17. B ayer Pharma AG. Xarelto → (rivaroxaban) Summary of Product Characteristics. 2013. Available at: Http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/ 000944/WC500057108.pdf . Accessed 9 April 3013
18. Mills RM, Berkowitz RD, Damaraju CV, Jennings LK, Wildgoose P. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis aft er total joint replacement: The Safe, Simple Transitions (SST) study . Thromb Res. 2012; 130: 709- 15
19. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al . Dabigatran etexilate- A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity . Thromb Haemost. 2010; 103: 1116- 27
20. B oehringer Ingelheim International GmbH. Pradaxa → (dabigatran etexilate) Summary of Product Characteristics . 2013 . Available at: Http:// www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/ 000829/WC500041059.pdf . Accessed 9 April 2013
21. Douxfi ls J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specifi c coagulation assays . Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985- 97
22. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al . Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012; 107: 379- 87
23. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, et al. Accurate determination of rivaroxaban levels requires diff erent calibrator sets but not addition of antithrombin . Thromb Haemost. 2012; 108 : 191-8
24. McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT . Eff ects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation . Blood Coagul Fibrinolysis. 2005; 16: 173- 6
25. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specifi c for measuring direct Factor Xa inhibitors (rivaroxaban) in plasma . Thromb Haemost. 2010; 104: 1078- 9
26. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, et al . Rivaroxaban: Quantifi cation by anti-FXa assay and infl uence on coagulation tests: A study in 9 Swiss laboratories . Thromb Res. 2012 ; 129 : 492-8
27. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement . Thromb Haemost. 2008 ; 100 : 453-61
28. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention . Clin Pharmacokinet. 2011 ; 50 : 675-86
29. G erotziafas G T, H atmi M, S amama M M, E lalamy I . O ptimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res. 2012; 129: 101- 3
30. Tichelaar V, de Jong H, Nijland H, Kluin-Nelemans H, Meijer K, Mulder A . Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays . Thromb Haemost. 2011; 106: 990- 2
31. The EINSTEIN Investigators. O ral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499- 510
32. Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing . Thromb Haemost. 2011 ; 105 : 385-6
33. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo eff ects of lowdose rivaroxaban on specifi c coagulation assays and coagulation factor activities in patients under real life conditions . Thromb Haemost. 2013 ; 109 : 127-36
34. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011; 127: 457- 65
35. Haas S . F acts and artefacts of coagulation assays for Factor Xa inhibitors. Thromb Haemost. 2010; 103: 686- 8
36. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011; 49: 761- 72
37. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery . Clin Pharmacokinet. 2008; 47: 203- 16
38. Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor . Thromb Haemost. 2012; 108: 876- 86
39. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M . Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects . Circulation. 2011 ; 124 : 1573-9